Abstracts tagged "citrulline and rheumatoid arthritis (RA)"

Abstract Number: 2046 • 2018 ACR/ARHP Annual Meeting
Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies
Mandar Bawadekar¹, Zihao Zheng², Alan J. Bridges^3,4, Michael A. Newton⁵ and Miriam A. Shelef^1,4, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ²Departments of Statistics, University of Wisconsin - Madison, Madison, WI, ³Medicine, University of Wisconsin - Madison, Madison, WI, ⁴William S. Middleton Memorial Veterans Hospital, Madison, WI, ⁵Departments of Statistics and of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Rheumatoid arthritis patients produce a variety of anti-citrullinated protein antibodies (ACPAs) as well as antibodies that bind homocitrullinated and malondialdehyde-acetaldehyde adducted proteins leading to…
Abstract Number: 1549 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Periodontal Disease: Salivary ACPA Levels and Clinical Presentation
Zoltan Szekanecz¹, Ildiko Tar², Eva Csösz³, Eva Veiszenbacher⁴, Edit Végh⁵, Kinga Bágyi⁶, Karin Lundberg⁷, Nastya Kharlamova⁸ and Ildiko Márton², ¹Department of Rheumatology, University of Debrecen Faculty of Medicine, Debrecen, HU, ²Department of Periodontology, University of Debrecen Faculty of Dentistry, Debrecen, Hungary, ³Center for Molecular Medicine, University of Debrecen Faculty of Medicine, Debrecen, Hungary, ⁴Faculty of Dentistry, University of Tirgu Mures, Tirgu Mures, Romania, ⁵Department of Rheumatology, University of Debrecen Faculty of Medicine, Debrecen, Hungary, ⁶Department of Restorative Dentistry, University of Debrecen Faculty of Dentistry, Debrecen, Hungary, ⁷Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden
Background/Purpose: We evaluated the periodontal involvement of rheumatoid arthritis (RA) patients, and we correlated with various laboratory biomarkers including lipids, autoantibodies, serum vitamin D levels,…
Abstract Number: 422 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrulline From Rheumatoid Arthritis Patients Also Bind Homocitrulline
Mathias Scinocca¹, Radha Joseph², David A. Bell³, Ewa Cairns³ and Lillian J. Barra³, ¹Microbiology and Immunology, Schulich School of Medicine and Dentistry, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: Antibodies to citrullinated proteins/peptides (ACPA) are specific for Rheumatoid Arthritis (RA). One of ACPA’s targets is citrullinated fibrinogen (citfib) and it is found in…
Abstract Number: 1770 • 2012 ACR/ARHP Annual Meeting
Recognition of Citrullinated and Carbamylated Proteins by Human Antibodies: Specificity, Cross-Reactivity and the “AMC-Senshu” Method
Jing Shi¹, George Janssen², Peter van Veelen², Janwouter Drijfhout², Antony Cerami³, Tom Huizinga⁴, Leendert A. Trouw⁵ and René E.M. Toes⁴, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Immunohematology and Bloodbank, LUMC, Leiden, Netherlands, ³Nephrology, LUMC, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play an important role in the diagnosis and prognosis of Rheumatoid Arthritis (RA). The Anti-Modified Citrulline (AMC) (‘Senshu’) method is…
Abstract Number: 1689 • 2012 ACR/ARHP Annual Meeting
Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies: A Novel Biomarker with Clinical and Mechanistic Implications in Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Herbert Bull³, Felipe Andrade⁴ and Antony Rosen¹, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Consultant, Westfield, NJ, ⁴Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Peptidylarginine deiminases (PADs) have emerged as key participants in the pathogenesis of rheumatoid arthritis (RA) due to their expression in inflamed RA synovium and…
Abstract Number: 1190 • 2012 ACR/ARHP Annual Meeting
Fine Specificity of Anti-Citrullinated Peptide Antibodies Discloses a Heterogeneous Antibody Population in Rheumatoid Arthritis (RA)
John D. Goules, Andreas V. Goules and Athanasios G. Tzioufas, Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are highly specific for the diagnosis of patients with RA. However, the predominant B cell epitopes have not yet been…
Abstract Number: 436 • 2012 ACR/ARHP Annual Meeting
Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis
Youngkyun Kim¹, Su-Jin Moon², Hyoju Yi² and Ji Hyeon Ju³, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA
Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].